Local augmented angiotensinogen secreted from apoptotic vascular endothelial cells is a vital mediator of vascular remodelling

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Wu, Shyh Jong ^a   Soulez, Mathilde ^b   Yang, Ya Hui ^c   Chu, Chih Sheng ^a,d,e   Shih, Shih Chuan ^a   Hébert, Marie Josée ^f   Kuo, Mei Chuan ^d   Hsieh, Ya Ju ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c FOOYIN UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^f NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSINOGEN; BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; LISINOPRIL; LOSARTAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE EXPRESSION; HORMONE RELEASE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL LINE; METABOLISM; RAT; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANIMALS; APOPTOSIS; CELL LINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LISINOPRIL; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PEPTIDYL-DIPEPTIDASE A; RATS; VASCULAR REMODELING;

EID: 84940063653     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132583     Document Type: Article

References (39)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420(6917):868-74. doi: 10.1038/nature01323 PMID: 12490960.
2. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005; 111 (17):2257-73. doi: 10.1161/01.CIR.0000163587.36485.A7 PMID: 15867193.
3. Post MJ, de Smet BJ, van der Helm Y, Borst C, Kuntz RE. Arterial remodeling after balloon angioplasty or stenting in an atherosclerotic experimental model. Circulation. 1997; 96(3):996-1003. PMID: 9264511.
4. Cailhier JF, Laplante P, Hebert MJ. Endothelial apoptosis and chronic transplant vasculopathy: recent results, novel mechanisms. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2006; 6(2):247-53. doi: 10.1111/j.1600-6143.2005.01165.x PMID: 16426308.
5. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circulation research. 2002; 90(3):251-62. PMID: 11861412.
6. Iwai N, Izumi M, Inagami T, Kinoshita M. Induction of renin in medial smooth muscle cells by balloon injury. Hypertension. 1997; 29(4):1044-50. PMID: 9095097.
7. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arteriosclerosis, thrombosis, and vascular biology. 1999; 19(7):1623-9. PMID: 10397679.
8. Ohishi M, Dusting GJ, Fennessy PA, Mendelsohn FA, Li XC, Zhuo JL. Increased expression and colocalization of ACE, angiotensin II AT(1) receptors and inducible nitric oxide synthase in atherosclerotic human coronary arteries. International journal of physiology, pathophysiology and pharmacology. 2010; 2(2):111-24. PMID: 21179388; PubMed Central PMCID: PMC3004229.
9. Morishita R, Gibbons GH, Tomita N, Zhang L, Kaneda Y, Ogihara T, et al. Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function. Arteriosclerosis, thrombosis, and vascular biology. 2000; 20(4):915-22. PMID: 10764654.
10. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001; 104(22):2716-21. PMID: 11723025.
11. Aoki M, Nata T, Morishita R, Matsushita H, Nakagami H, Yamamoto K, et al. Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension. 2001; 38(1):48-55. PMID: 11463759.
12. Hillebrands JL, Rozing J. Chronic transplant dysfunction and transplant arteriosclerosis: new insights into underlying mechanisms. Expert reviews in molecular medicine. 2003; 5(2):1-23. doi: 10.1017/S146239940300557X PMID: 14987399.
13. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovascular diabetology. 2006; 5:4. doi: 10.1186/1475-2840-5-4 PMID: 16504104; PubMed Central PMCID: PMC1434727.
14. Soulez M, Pilon EA, Dieude M, Cardinal H, Brassard N, Qi S, et al. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circulation research. 2012; 110(1):94-104. doi: 10.1161/CIRCRESAHA.111.250431 PMID: 22076637.
15. Raymond MA, Vigneault N, Luyckx V, Hebert MJ. Paracrine repercussions of preconditioning on angiogenesis and apoptosis of endothelial cells. Biochemical and biophysical research communications. 2002; 291(2):261-9. doi: 10.1006/bbrc.2002.6449 PMID: 11846399.
16. Wu SJ, Chiang FT, Chen WJ, Liu PH, Hsu KL, Hwang JJ, et al. Three single-nucleotide polymorphisms of the angiotensinogen gene and susceptibility to hypertension: single locus genotype vs. haplotype analysis. Physiological genomics. 2004; 17(2):79-86. doi: 10.1152/physiolgenomics.00133.2003 PMID: 14970360.
17. Wu SJ, Hsieh TJ, Kuo MC, Tsai ML, Tsai KL, Chen CH, et al. Functional regulation of Alu element of human angiotensin-converting enzyme gene in neuron cells. Neurobiology of aging. 2013; 34(7):1921 e1-7. doi: 10.1016/j.neurobiolaging.2013.01.003 PMID: 23391425.
18. Cassis LA, Lynch KR, Peach MJ. Localization of angiotensinogen messenger RNA in rat aorta. Circulation research. 1988; 62(6):1259-62. PMID: 3383369.
19. Akishita M, Horiuchi M, Yamada H, Zhang L, Shirakami G, Tamura K, et al. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiological genomics. 2000; 2(1):13-20. PMID: 11015577.
20. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008; 451(7181):904-13. doi: 10.1038/nature06796 PMID: 18288179.
21. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. The Journal of clinical investigation. 1994; 93(1):339-46. doi: 10.1172/JCI116965 PMID: 8282805; PubMed Central PMCID: PMC293775.
22. Liu S, Xie Z, Zhao Q, Pang H, Turk J, Calderon L, et al. Smooth muscle-specific expression of calcium-independent phospholipase A2beta (iPLA2beta) participates in the initiation and early progression of vascular inflammation and neointima formation. The Journal of biological chemistry. 2012; 287 (29):24739-53. doi: 10.1074/jbc.M112.340216 PMID: 22637477; PubMed Central PMCID: PMC3397901.
23. Yao HL, Gao FH, Li ZZ, Wu HX, Xu MD, Zhang Z, et al. Monocyte chemoattractant protein-1 mediates angiotensin II-induced vascular smooth muscle cell proliferation via SAPK/JNK and ERK1/2. Molecular and cellular biochemistry. 2012; 366(1-2):355-62. doi: 10.1007/s11010-012-1315-x PMID: 22527942.
24. Gould AB, Green D. Kinetics of the human renin and human substrate reaction. Cardiovascular research. 1971; 5(1):86-9. PMID: 4322712.
25. Reid IA, Morris BJ, Ganong WF. The renin-angiotensin system. Annual review of physiology. 1978; 40:377-410. doi: 10.1146/annurev.ph.40.030178.002113 PMID: 205167.
26. Danilov SM, Gordon K, Nesterovitch AB, Lunsdorf H, Chen Z, Castellon M, et al. An angiotensin I-converting enzyme mutation (Y465D) causes a dramatic increase in blood ACE via accelerated ACE shedding. PloS one. 2011; 6(10):e25952. doi: 10.1371/journal.pone.0025952 PMID: 21998728; PubMed Central PMCID: PMC3187827.
27. Zhuo JL, Froomes P, Casley D, Liu JJ, Murone C, Chai SY, et al. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation. 1997; 96(1):174-82. PMID: 9236432.
28. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996; 94(11):2756-67. PMID: 8941100.
29. Yaghini FA, Song CY, Lavrentyev EN, Ghafoor HU, Fang XR, Estes AM, et al. Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation. Hypertension. 2010; 55(6):1461-7. doi: 10.1161/HYPERTENSIONAHA.110. 150029 PMID: 20439821; PubMed Central PMCID: PMC2916227.
30. Ding Y, Stec DE, Sigmund CD. Genetic evidence that lethality in angiotensinogen-deficient mice is due to loss of systemic but not renal angiotensinogen. The Journal of biological chemistry. 2001; 276 (10):7431-6. doi: 10.1074/jbc.M003892200 PMID: 11096065.
31. Kang N, Walther T, Tian XL, Bohlender J, Fukamizu A, Ganten D, et al. Reduced hypertension-induced end-organ damage in mice lacking cardiac and renal angiotensinogen synthesis. Journal of molecular medicine. 2002; 80(6):359-66. doi: 10.1007/s00109-002-0326-6 PMID: 12072911.
32. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121(7):948-54. doi: 10.1161/CIRCULATIONAHA.109.192666 PMID: 20177011.
33. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009; 119(4):530-7. doi: 10.1161/CIRCULATIONAHA.108.826214 PMID: 19153265.
34. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The New England journal of medicine. 2000; 342(3):145-53. doi: 10.1056/NEJM200001203420301 PMID: 10639539.
35. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001; 103(7):919-25. PMID: 11181464.
36. Glicklich D, Gordillo R, Supe K, Tapia R, Woroniecki R, Solorzano C, et al. Angiotensin converting enzyme inhibitor use soon after renal transplantation: a randomized, double-blinded placebo-controlled safety study. Clinical transplantation. 2011; 25(6):843-8. doi: 10.1111/j.1399-0012.2010.01372.x PMID: 21158922.
37. Remko M. Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitors. Chemical Papers. 2007; 61(2):133-41. doi: 10.2478/s11696-007-0010-y
38. Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A. Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS letters. 2007; 581(18):3449-54. doi: 10.1016/j.febslet.2007.06.048 PMID: 17618628.
39. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998; 97(14):1411-20. PMID: 9577953.